Headlines about Auris Medical (NASDAQ:EARS) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Auris Medical earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 48.0687205672861 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Separately, ValuEngine upgraded shares of Auris Medical from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

Auris Medical remained flat at $$0.27 during trading on Friday, MarketBeat reports. 534,562 shares of the company were exchanged, compared to its average volume of 997,162. Auris Medical has a 52-week low of $0.26 and a 52-week high of $9.50. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of -3.12.

Auris Medical (NASDAQ:EARS) last released its earnings results on Tuesday, May 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.

Auris Medical Company Profile

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Read More: Short Selling

Insider Buying and Selling by Quarter for Auris Medical (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.